Results 141 to 150 of about 462,772 (320)

Lifestyle Management in Menopause: A Systematic Review of Women With Premature Ovarian Insufficiency

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Premature ovarian insufficiency (POI), the loss of ovarian function before age 40, increases the risk of cardiovascular disease, low bone mineral density, dementia and psychological distress. Lifestyle interventions reduce chronic disease risk in other populations and, with hormone therapy, may improve health outcomes in POI.
Ladan Yeganeh, Nathalie Vermeulen, Carolyn Ee, Helena Teede, Amanda J. Vincent   +4 more
wiley   +1 more source

The 2024 UK clinical guideline for the prevention and treatment of osteoporosis

Archives of Osteoporosis
The National Osteoporosis Guideline Group (NOGG) has updated the revised UK guideline for the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women, and men age 50 years and older.
C. Gregson, David J. Armstrong, C. Avgerinou, J. Bowden, Cyrus Cooper, L. Douglas, J. Edwards, N. Gittoes, N. Harvey, J. Kanis, S. Leyland, Rebecca Low, E. McCloskey, Katie Moss, Jane Parker, Z. Paskins, K. Poole, D. M. Reid, M. Stone, J. Tomson, Nic Vine, J. Compston   +21 more
semanticscholar   +1 more source

Teriparatide Topical Delivery Supports Osseointegration in Ovariectomized Rats Receiving Cafeteria Diet and Bisphosphonate: An In Vivo Experimental Study

Clinical Oral Implants Research, EarlyView.
ABSTRACT Background Postmenopausal osteoporosis associated with cafeteria diet and bisphosphonate therapy may impair peri‐implant bone repair. Therefore, strategies to enhance osseointegration are needed. Aim This study investigated whether teriparatide‐coated implant surfaces enhance osseointegration in a rodent model of estrogen deficiency (OVX) and ...
Ana Cláudia Ervolino da Silva, Fábio Roberto de Souza Batista, Jaqueline Suemi Hassumi, Naara Gabriela Monteiro, Marina Santos Fernandes, Luana Marotta Reis Vasconcellos, Gabriel Mulinari‐Santos, Reinhard Gruber, Paulo Noronha Lisboa‐Filho, Roberta Okamoto   +9 more
wiley   +1 more source

The Short-Term Effects of Strontium Ranelate on Pain and Bone Mineral Density in Postmenopausal Women with Osteoporosis

, 2012
Aim: Minerals and trace elements affect bone formation and resorption through direct or indirect effects on bone cells or bone mineral. Strontium has several effects on bone cells and anabolic actvity.
Halil Koyuncu, Selma Eşen, Meryem Gül Erden   +2 more
core   +1 more source

YTHDF3 Enhances Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells in Osteoporosis by Promoting TBX19 Expression

Cell Proliferation, EarlyView.
In this study, OP‐BMSCs were successfully isolated from OVX osteoporotic rats. Mechanistic investigations revealed that the RNA‐binding protein YTHDF3 significantly upregulates Tbx19 expression by enhancing the stability of Tbx19 mRNA. Elevated Tbx19 levels, in turn, activate key osteogenic molecules, effectively promoting the differentiation of OP ...
Qianke Tao, Qiaonan Ye, Chengpeng Yang, Yuping Xie, Xuemei Long, Long Bai, Zhiyuan Zhang, Qianwei Li, Dan Tan, Jingang Xiao   +9 more
wiley   +1 more source

Weight Regain After Incretin Treatment: The Lean Mass Deficit Hypothesis and a Role for Testosterone Combination Therapy in Men

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1RA and triple (GIP)/GLP‐1RA/glucagon agonists achieve placebo‐subtracted weight loss of 15% to 22%. Their long‐term value depends on how well the weight loss is maintained and on the composition of weight loss, not only
Michael Zitzmann, Zsolt Bosnyak, Richard Jones, Monica Caliber   +3 more
wiley   +1 more source

Comprarison of Risendronate and Raloxifene Treatment in Postmenopausal Osteoporosis - Original Investigation

, 2006
Aim: The aim of this study was to compare the efficacy of risendronate and raloxifene treatments on bone mineral density (BMD) and biochemical markers of bone turnover in postmenopausal osteoporosis.
Cengiz Öner, Funda Taşçıoğlu, Onur Armağan, Dilek Koç Yılmaz, Ayşe Ekim   +4 more
core  

Sclerostin regulates bone morphogenetic protein (BMP) bioavailability through interactions with BMP complexes and fibrillin microfibrils

The FEBS Journal, EarlyView.
Sclerostin (SOST) is a multifunctional extracellular modulator of BMP and Wnt signaling. SOST binds with high affinity to fibrillin‐1 and fibrillin‐2, localizing it to fibrillin microfibrils and regulating its extracellular bioavailability. Fibrillin‐bound SOST cannot engage BMP‐7 prodomain (PD) complexes, revealing a competitive mechanism that ...
Annkatrin Correns, Fady Marcous, Steffen Lütke, Matthias Mörgelin, Philipp Barnowski, Ariane G. Furlan, Nathalie H. Schröder, Bodo Levkau, Sarah Riek, Martin Mollenhauer, Manuel Koch, Gerhard Sengle   +11 more
wiley   +1 more source

New advances in the study of postmenopausal osteoporosis and arteriosclerosis: Exploration of metabolite changes and their mechanisms

Archives of Gerontology and Geriatrics Plus
Postmenopausal women face a significantly increased risk of osteoporosis and arteriosclerosis due to a marked decline in estrogen levels, making it an important issue in public health. In recent years, metabolomic studies have revealed dynamic changes in
Yang Lei, Li Misi, Chen Xiaoyun, An Yangxin, Hu Xueqin, Li Weijuan   +5 more
doaj   +1 more source

The Comparison of Effects of Alendronate and Raloxifene Treatment in Postmenopausal Women with Osteoporosis - Original Investigation

, 2006
This study was performed to assess and compare the effects of raloxifene and alendronate for the treatment of postmenopausal osteoporosis. Thirty-two women with postmenopausal osteoporosis (raloxifene group:16 patients, alendronate group: 16 patients ...
Ayhan Erkek, Cavidan Ay, Ömer Faruk Şendur, Bengü Beydağ Odabaşı, Gülcan Gürer   +4 more
core